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Background: Evidence suggests that Plasmodium knowlesi malaria in Sarawak, Malaysian Borneo remains zoonotic,
meaning anti-malarial drug resistance is unlikely to have developed in the absence of drug selection pressure.
Therefore, adequate response to available anti-malarial treatments is assumed.
Methods: Here the ex vivo sensitivity of human P. knowlesi isolates in Malaysian Borneo were studied, using a WHO
schizont maturation assay modified to accommodate the quotidian life cycle of this parasite. The in vitro sensitivities
of P. knowlesi H strain adapted from a primate infection to in vitro culture (by measuring the production of
Plasmodium lactate dehydrogenase) were also examined together with some assays using Plasmodium falciparum
and Plasmodium vivax.
Results: Plasmodium knowlesi is uniformly highly sensitive to artemisinins, variably and moderately sensitive to
chloroquine, and less sensitive to mefloquine.
Conclusions: Taken together with reports of clinical failures when P. knowlesi is treated with mefloquine, the data
suggest that caution is required if using mefloquine in prevention or treatment of P. knowlesi infections, until
further studies are undertaken.
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From its natural simian hosts in Southeast Asia, Plasmo-
dium knowlesi has emerged as a significant human
pathogen, particularly in Malaysian Borneo [1-3]. Human
P. knowlesi infections cause febrile illnesses that can rap-
idly progress to severe and sometimes fatal outcomes [4].
Ominously, the incidence of P. knowlesi malaria is increas-
ing in geographic areas where Plasmodium falciparum
and Plasmodium vivax are coming under control, thereby
threatening the aim of eliminating malaria [5]. Deter-
mining the efficacy of conventional anti-malarials against
P. knowlesi is a priority, particularly as there are no
reports of anti-malarials assessed against human isolates of
P. knowlesi ex vivo.* Correspondence: s.krishna@sgul.ac.uk
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stated.Here, the drug sensitivity profiles of P. knowlesi isolates
obtained from patients being recruited into a study of the
pathophysiology of knowlesi malaria in an endemic area of
Sarawak, Malaysian Borneo were investigated. Currently,
the WHO recommends artemisinin-based combination
therapy (ACT) as first-line treatment for malaria in most
endemic areas, so artemisinin and its clinically useful de-
rivatives artesunate, dihydroartemisinin (DHA) and arte-
mether were tested. Mefloquine, used as a partner drug in
certain artemisinin-based combinations and in prophylaxis
against malaria, and chloroquine that is recommended for
treatment of Plasmodium malariae (the species which
P. knowlesi is often confused with when diagnosed by
microscopy) were also included. In addition, results from
P. falciparum and P. vivax studied contemporaneously
are presented, together with those obtained with the H
strain laboratory isolate of P. knowlesi (cultured in vitro
in rhesus erythrocytes) to confirm the methodologies
used. Insights into the drug susceptibility patterns of this
important emerging parasite, may prove useful in guidingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Plasmodium isolates were obtained from patients pre-
senting to hospitals in Sarikei and Sibu. Informed writ-
ten consent was obtained from all patients entered into
this study, which was approved by the Malaysian Ministry
of Health’s Medical Research and Ethics Committee, and
the Sarawak State Planning Unit. Infecting species was
confirmed by Plasmodium species-specific nested-PCR
assays [6] and only patients with single species infections
were retained in the study.
Blood collection and ex vivo parasite development in
growth assays
Pre-treatment venous blood from each patient was col-
lected into EDTA. Parasitaemia and the asexual stage of
development were determined by Giemsa-stained thin
film microscopy. Whole blood (~2.5 ml) was washed twice
without centrifugation to avoid haemolysis, before resus-
pending in RPMI 1640 complete medium supplemented
with 20 mM D-glucose, 40 mM HEPES, 25 mg/l gentami-
cin sulphate, and 15% v/v human AB plasma with 0.2 mM
hypoxanthine.
Growth inhibition by anti-malarials was assessed by
quantifying schizont maturation using an adapted WHO
Mark III assay [7]. Species of Plasmodium tested and
the time lag in maturation seen previously ex vivo were
allowed for in these assays [8]. While more complex
counting procedures have been used to study P. vivax
parasites that, like P. knowlesi, have mature parasites
present in circulating blood [9], only the timing of as-
says was altered. This is because the P. knowlesi isolates
contained predominantly immature parasites (Table 1)
and results from a parallel study on tightly synchronisedTable 1 Patient isolate data
Isolate Species % starting parasitaemia % schizont at start of assa
P0002 Pk 0.4 15
P0003 Pk 0.6 10
P0006 Pk 0.8 33
P0009 Pk 7.0a 17
P0010 Pk 0.8 6
P0011 Pk 1.3 8
P0007 Pf 2.0a 0
P0001 Pv 0.5 20
P0013 Pv 0.5 30
aAbove Mark III assay cut-off (for examination of P. falciparum mono-infections), ass
of blood, and was used undiluted. Note that in both cases good schizont developm
For each isolate, the species, parasitaemia and change in development over time arimmature laboratory P. knowlesi H strain parasites with
artesunate using the pLDH (see below) and Mark III assays
were comparable with each other and with the data derived
from isolates (see Results).
Aliquots (100 μl) of no drug control and serial dilu-
tions of the anti-malarial compounds in culture medium
(final concentrations of 0.25 to 25 nM for artemisinin
and derivatives and 1.25 nM to 1 μM for chloroquine
and mefloquine) were dispensed into 96-well plates, and
parasites were added (100 μl at 2% haematocrit). Incuba-
tion was in 5% O2, 5% CO2, 90% N2 at 37°C until the
majority of parasites reached the schizont stage (with at
least 3 nuclei after 12–17 h for P. knowlesi). Monitoring
of maturation was undertaken every 2 h by examination
of fixed, Giemsa stained thin blood films, taken from a
parallel culture to those of the drug exposed cultures.
When at least half of the parasites in the monitoring cul-
ture had reached the schizont stage of development, the
drug exposed cultures and their controls were harvested,
as thick films on glass slides, and examined. The duration
of in vitro development for each isolate (as determined
above), which also equates to the time of drug exposure, is
given in Table 1. Thick films were fixed by air drying for at
least 24 h, stained with Giemsa, and mounted to protect
slides during transportation.
As thick films are easily damaged, five replicates were
prepared for each drug concentration and 3 replicates
then counted for each experimental condition. Count-
ing was in a blinded fashion to avoid bias. Thick films
were counted according to the WHO Mark III proto-
col. At least 200 asexual parasites were counted. Fields
of view were consecutive, starting at the left edge of
each blood film and moving stepwise in a uniform dir-
ection (to ensure no overlap). Asexual parasites were
grouped into either trophozoites or schizonts (defined
as asexual parasites displaying 1–2 nuclei and 3 or more










uming a parasitaemia of 1.6% equates to approximately 80,000 parasites per μl
ent was observed.
e presented.
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dehydrogenase (pLDH)
Rhesus monkey red blood cells for in vitro P. knowlesi
culture were obtained under protocols approved by the
independent institutional ethical committee (DEC) ac-
cording to Dutch and European laws.
The efficacy of the anti-malarial compounds was
also assessed in vitro against the laboratory maintained
P. knowlesi H strain [10,11], by measuring the produc-
tion of pLDH [12]. pLDH catalyzes the conversion of
3-acetylpyridine adenine dinucleotide (APAD) and lactate
to APADH and pyruvate. The enzyme diaphorase subse-
quently converts nitro blue tetrazolium (NBT) to nitro blue
formazan (NBF), using APADH as a reducing agent. NBF
can be measured at a wavelength of 655 nm. Serial dilu-
tions of the anti-malarial compounds (100 μl in culture
medium) and including a no drug control were dispensed
into 96-well plates, to which tightly synchronized (by ala-
nine lysis) early ring-stage infected erythrocytes (100 μl at
2% haematocrit and 2% parasitaemia in culture medium)
were added. The plates were then placed in 3% O2, 7%
CO2, 90% N2 at 37°C for 22 h to mature (just prior to para-
site release). Growth was halted and drug removed, by
washing twice in ice-cold PBS. Erythrocytes were lysed by
freezing at −20°C and thawing. Aliquots of 0.5 mg/ml of
NBT, 1 U/ml diaphorase and 50 μg/ml APAD in LDH buf-
fer (100 mM Tris–HCl, pH 8.0, 50 mM Na L-lactate, 2.5%
v/v Triton X-100) were added to the thawed cell pellets
and incubated for 30 min in the dark at room temperature
with shaking. The optical density (OD) at 655 nm of each
well was measured in a BioRad 680 microplate reader.
OD655 values were used to calculate growth by comparing
the OD655 values at each drug concentration with that of
the no drug control. To test the efficacy of artemisinin,
artemether, artesunate and DHA, preparations of final
concentrations of 0.1 nM to 25 nM were used, and for
chloroquine and mefloquine, final concentrations of
1.25 nM to 1 μM were used.
IC50 values and sequence alignments
Dose–response data were modeled using a four-parameter
fit and a variable slope, using Prism (Version 4.0a). Good-
ness of fit was assessed by R2, and either noted in the
text or highlighted if < 0.8 in tables and figures. For
the schizont maturation assay, the top parameter was
constrained to 100% for assays using artemisinins but
not for mefloquine or chloroquine. For the pLDH assay,
the top and bottom parameters were constrained to
100 and 0, respectively, for all drugs and, for the 3H-
hypoxanthine incorporation assay, the top parameter
was constrained to 100. Data are summarized as a mean
and 95% CI for replicates of single parasite assays and a
mean ± SEM for results from multiple independent para-
site assays.The P. knowlesi and P. vivax orthologues of P. falcip-
arum CRT, MDR1, and ATP6 (proteins associated with
modulating sensitivities to chloroquine, mefloquine and
artemisinins [13]), were aligned with P. falciparum 3D7
strain, as a drug sensitive control. H strain and Sal-1
strain sequences were used for P. knowlesi and P. vivax,
respectively. Wild-type and polymorphism sequence data
were taken from PlasmoDB [14]. Alignments were per-
formed in MacVector (version 11.0.2).
Results
Patient recruitment
Patient isolate data from those obtained in Sarikei and
Sibu hospitals, between March and September 2010, are
shown in Table 1. A total of nine patients were recruited
into this study, six with P. knowlesi, two with P. vivax
and one with P. falciparum monoinfections. Infections
were initially diagnosed by microscopy and confirmed later
by nested PCR [2,6].
Parasite development
In vitro development data for each isolate used dur-
ing growth assays are shown in Table 1. P. knowlesi
field isolates were seeded into growth assays with a
starting parasitaemia ranging from 0.4 to 7%. The per-
centage of schizonts present at the start of the assays
ranged from 6 to 33%. Good in vitro development was
demonstrated for all P. knowlesi field isolates, with 53
to 94% of asexual parasites reaching the schizont stage,
over a development period of 12 to 17 h. Development
was similar for P. falciparum and P. vivax field isolates
(Table 1).
Growth assays: schizont maturation
Dose–response curves were used to derive IC50 values,
which are presented in Figure 1, together with mean
values in Table 2. All the isolates from humans were
sensitive to artemisinin and its derivatives, with IC50
values in the low nM range (from 0.38 to 6.8 nM).
The IC50 values for chloroquine on P. knowlesi from
humans were relatively high, with values ranging from
11 to 38 nM but were similar to those derived for
the single P. falciparum isolate (28 (20 to 38) nM;
R2 = 0.93) and the two P. vivax isolates (33 (10 to 110)
and 18 (11 to 27) nM; R2 = 0.45 and 0.95, respectively)
that were studied.
Plasmodium knowlesi isolates were least sensitive to
mefloquine, with a mean IC50 value of 26 nM (Table 2).
The IC50 value for mefloquine on the single P. falcip-
arum field isolate (6.3 (2.5 to 16) nM; R2 = 0.97) was
four-fold less than that of the average P. knowlesi IC50
value and 2.5-fold less than the lowest P. knowlesi IC50
value (16 (12 to 22) nM; R2 = 0.96).
Figure 1 IC50 values for anti-malarial drugs against Plasmodium
isolates, using the schizont maturation assay. Data points
represent mean IC50 values (nM) derived from single experiments
performed in triplicate. Plasmodium knowlesi (black symbols), P. vivax
(red symbols) and P. falciparum (green symbols). Filled symbols
indicate R2 values≥ 0.8, with unfilled symbols indicting R2 values < 0.8.
Mefloquine, MQ; Chloroquine, CQ; Artemisinin, AR; Artemether, AM;
Artesunate, AS; Dihydroartemisinin, DHA. Note that there is only
mefloquine data for one of the two P. vivax isolates.
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To validate the results of the drug assays on P. knowlesi
from patients, anti-malarials were assessed against the
well characterized P. knowlesi H strain grown in vitro in
rhesus erythrocytes. To determine whether data gener-
ated by the pLDH method (as used to study the H
strain) would be comparable with the adapted schizont
maturation method (as used in the field study) a parallel
study was performed, using artesunate. The IC50 value
for artesunate against the H strain was 2.0 (0.93 to 4.2) nM
(R2 = 0.39), using the pLDH assay (from a single experi-
ment repeated in quintuplicate), and 1.2 (0.88 to 1.6) nM
(R2 = 0.95), using the schizont maturation assay (from a
single experiment repeated in triplicate), demonstrating
that the two assay methods are comparable, at least in theTable 2 P. knowlesi drug sensitivity data
Drug IC50 values (nM) for
P. knowlesi isolates
(maturation assay)a
IC50 values (nM) for
P. knowlesi H strain
(pLDH assay)b
Mefloquine 26 (± 3.1) 25 (7.4 to 81)c
Chloroquine 23 (± 4.8) 3.2 (2.2 to 4.7)
Artemisinin 2.1 (± 0.99) 0.80 (0.35 to 1.9)c
Artemether 0.90 (± 0.19) 0.84 (0.34 to 2.1)c
Artesunate 0.90 (± 0.12) 2.0 (0.93 to 4.2)c
DHA 1.6 (± 0.92) 0.79 (0.62 to 1.0)
aMean (± SEM), from 6 independent experiments (each of which was performed
in triplicate).
bMean (95% CIs), from a single experiment repeated in quintuplicate.
cR2 < 0.8.
IC50 values are presented for six anti-malarials on P. knowlesi field isolates and
laboratory H strain.case of artemisinins. Further IC50 values derived from
pLDH assays are presented in Table 2. All IC50 values for
field isolates and the P. knowlesi H strain for artemisinins
are highly comparable.
For mefloquine, the IC50 value against the laboratory
H strain (25 (7.4 to 81) nM; R2 = 0.40) was nearly identi-
cal to the mean IC50 value of human isolates (26 nM).
The IC50 values suggest that P. knowlesi may be intrin-
sically insensitive to mefloquine. To ensure that the mef-
loquine stock used in field studies had not degraded
during the study, an aliquot was tested after shipping
it back to St. George’s, University of London after the
study. Using hypoxanthine incorporation as a measure
of growth [15] in a single assay (performed in quadru-
plicate) with P. falciparum (3D7) parasites cultured
in vitro in human erythrocytes, the IC50 value was 9.7
(5.5 to 17) nM (R2 = 0.89), confirming that potency of
mefloquine was maintained.
Interestingly, the H strain was over 7-fold more sensitive
to chloroquine than the average value for field isolates,
having an IC50 value of 3.2 (2.2 to 4.7) nM (R
2 = 0.86). This
value was also well below the lowest calculated IC50 value
(11 (5.3 to 24) nM; R2 = 0.94) for a field isolate.
Sequence alignments
Point mutations associated with change in the sensi-
tivity of P. falciparum to chloroquine, mefloquine and
the artemisinins [13] were analysed, and similarities and
differences in sequences encoded by P. knowlesi and
P. vivax homologues are reported in Figure 2. Known
loci at which mutations can reduce drug sensitivity were
highly conserved between P. knowlesi H, P. vivax Sal-1
MDR1 homologues and MDR1 in drug sensitive P. fal-
ciparum 3D7. PfATP6 orthologues demonstrated poly-
morphism in amino acids in about two thirds of theFigure 2 Alignment of CRT, ATP6, and MDR1 homologues of
P. knowlesi H strain and P. vivax Sal-1 strain, against P. falciparum
3D7 and strains with known point mutations associated with drug
resistance. Amino acids are colour coded, with green representing
the drug sensitive P. falciparum 3D7, and red representing amino
acid changes found in P. falciparum isolates that have a change in
drug sensitivity.
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sitivity, including L263 [16-18].
The CRT orthologues were fairly well conserved with
the exceptions of S219A, A220S, and R371M in the
chloroquine sensitive strain. These differences do not
confer chloroquine resistance to the P. knowlesi H strain.
Agreement in sequences in these polymorphic regions
was higher between P. knowlesi H and P. vivax Sal-1
than between either strain and P. falciparum 3D7 con-
sistent with a closer phylogenetic relationship between
the former species [19].
Discussion
In vitro culture of P. knowlesi has only recently been
achieved in human erythrocytes [20,21]. However, drug
sensitivity assays of natural human infections can only
be assessed in short term cultures. These allowed the
successful application of drug sensitivity micro-assays
such as the WHO Mark III micro-assay test after adap-
tation to the quotidian life cycle of the parasite and fre-
quent (every 2 to 2.5 h) monitoring of development to
allow assessment of when most parasites were mature
schizonts in control samples.
The excellent in vitro efficacy of the artemisinins against
both human P. knowlesi (mean IC50 values < 2.2 nM) and
the laboratory (H) strain is consistent with recent observa-
tions made on patients treated with artesunate, where no
mortality was observed after treatment [22]. These results
also agree with data from animal models, which demon-
strate the successful clearance of P. knowlesi parasites
from infected rhesus monkeys, by artemisinin in com-
bination therapy with naphthoquine [23]. In addition,
William et al. [24] in a retrospective analysis of clinical
cases of knowlesi malaria in Sabah, reported the suc-
cessful treatment of patients by artemether-lumefantrine
combination therapy. This study also noted that where
knowlesi malaria developed signs of severity, intravenous
artesunate was effective [24].
Intriguingly, chloroquine IC50 values from this field
study, including those derived against P. knowlesi (with
values ranging from 11 to 38 nM), were higher than that
of the laboratory P. knowlesi H strain (3.2 nM), although
the reason for this is unclear. In general, the values are
comparable with chloroquine-sensitive laboratory strains
of P. falciparum, having IC50 values ranging from 8 to
15 nM [25-27]. These values all fall below the 100 nM
threshold used to define chloroquine resistance [27,28]
and there is no evidence for clinical chloroquine resist-
ance reported in P. knowlesi. Chloroquine is effective
both as a monotherapy and when used in combination
with primaquine [1,24,29]. Consistent with these find-
ings, Tyagi et al. [30] have recently reported that CRT
(and DHFR) sequences from P. knowlesi clinical isolates
collected in the Andaman and Nicobar Islands, India,were all found to be wild-type (with close homology to
the CRT sequence of chloroquine sensitive P. falciparum
parasites – see Figure 2 and below). Nevertheless, contin-
ued monitoring of chloroquine sensitivity in P. knowlesi
might be prudent bearing in mind the history of chloro-
quine resistance development in other malarial species.
Evidence suggests that transmission of P. knowlesi to
humans in Sarawak remains zoonotic and, thus, osten-
sibly free from mefloquine drug selection pressure. How-
ever, results with mefloquine consistently showed a low
sensitivity in P. knowlesi field isolates, when compared
with that of P. falciparum. The mean IC50 value for meflo-
quine calculated for the 6 P. knowlesi isolates is 26 nM,
which is just above the value used to define mefloquine
resistance in P. falciparum (>24 nM) in some reports
[31,32] but well below that reported by others (>119 nM)
[33]. Importantly, the reduced P. knowlesi response in hu-
man isolates was also observed in the P. knowlesi H ex-
perimental line. Given the efficacy of the mefloquine used
was confirmed after the end of the study, these results in-
dicate an innate tolerance of P. knowlesi to mefloquine.
These findings also suggest the strong possibility of treat-
ment failure if mefloquine is used as mono or com-
bination therapy for P. knowlesi and is supported by
reports of mefloquine treatment failure in rhesus mon-
keys infected with P. knowlesi [34], as well as recent cases
of mefloquine treatment failure in humans with knowlesi
malaria [35]. On this basis, mefloquine should be used
with caution for the treatment of knowlesi malaria, or in-
deed for prophylaxis against malaria in areas where ac-
quiring knowlesi is a risk until larger studies have been
undertaken.
There is reasonable conservation of MDR1 sequences
between P. vivax Sal-1 and P. knowlesi H and the P. falcip-
arum 3D7 reference strain. Previous studies on P. falcip-
arum found that increased mdr1 copy number conferred a
mefloquine resistant phenotype [36] and risk of treatment
failure, although P. knowlesi mdr1 copy number in the iso-
lates reported in the current study have not been deter-
mined. Alignments of the P. vivax Sal-1 and P. knowlesi H
CRTand ATP6 orthologues with the P. falciparum 3D7 se-
quence revealed several polymorphic differences between
the P. vivax and P. knowlesi alignments and that of the
P. falciparum. These substitutions do not alter sensitivity
of P. knowlesi to artemisinins and give insights into the
possible contributions of these residues to artemisinin sen-
sitivity in P. falciparum.
Here, it has been established that it is possible to cul-
ture in vitro P. knowlesi in human erythrocytes in the
short term, when taken ex vivo. In addition, the success-
ful adaption of the schizont development assay to deter-
mine anti-malarial drug sensitivities of P. knowlesi field
isolates has been shown. Using this adapted method, this
study has demonstrated that chloroquine and artemisinin
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versely this study has shown poor sensitivity of P. knowlesi
field isolates and laboratory H strain to mefloquine, sug-
gesting innate reduced sensitivity of the parasite to this im-
portant anti-malarial drug.
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